Amarin Corporation plc

NASDAQ:AMRN

Biotechnology

Healthcare
$11.26 +1.84%

+$0.29 today

Market cap
$232.89M
Beta
0.82
P/E (TTM)
-9.9
EPS (TTM)
-$1.62
52W Low $12.30High $20.90

Volume 0.09M

Average 0.07M

AMRN Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Amarin Corporation plcNASDAQ: AMRN

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$1.72B, compared with -$1.68B a year earlier.

Context

  • Retained earnings amounted to 266.0% of total assets at the end of Q1 FY2026, up 9.1 pp from a year earlier.
  • Retained earnings grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -2.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.72B-0.6% QoQ
Last fiscal yearDec 2025
-$1.71B-2.3% YoY
Year agoMar 2025
-$1.68B-2.0% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.0%——
1 year-2.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(1.71B) USD
Year-over-year change
-2.3%

Retained Earnings vs competitors

How AMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -2.0% is the 2nd highest of 11, against a peer median of -39.9%.
  • Retained earnings amounts to 266.0% of total assets for AMRN, versus a peer median of 210.0%.
AMRN Competitors
Retained Earnings for AMRN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ANROAlto Neuroscience, Inc.Mar 2026-$227.87M USD-48.4%—82.5%
CLLSCellectis S.A.Mar 2026-$351.94M USD-1.2%—121.7%
KRROKorro Bio, Inc.Mar 2026-$403.47M USD-39.1%—219.7%
ENGNenGene Holdings Inc.Apr 2026-$432.01M USD-41.6%—140.5%
DBVTDBV Technologies S.A.Mar 2026-$440.7M USD-40.6%—165.4%
ACIUAC Immune S.A.Mar 2026-CHF 452.86M CHF-17.3%—329.5%
LRMRLarimar Therapeutics, Inc.Mar 2026-$464.44M USD-55.6%—222.7%
SLNSilence Therapeutics plcMar 2026-$577.53M USD-214.9%—501.7%
ALTAltimmune, Inc.Mar 2026-$672.05M USD-15.7%—200.2%
LYELLyell Immunopharma, Inc.Mar 2026-$1.64B USD-17.6%—468.8%
AMRNAmarin Corporation plcMar 2026-$1.72B USD-2.0%—266.0%
Peer median (excluding AMRN) —-39.9%—210.0%

Competitors are the stored peer set for AMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents219.45M217.67M199.25M121.04M134.86M
Short-term Investments234.67M91.7M121.41M173.18M167.93M
Net Receivables163.65M130.99M133.56M122.28M126.83M
Inventory234.68M228.73M258.62M166.05M195.91M
Other Current Assets3.92M20.02M525K12.85M24.35M
Total Current Assets878.73M689.1M724.98M595.4M649.88M
Property, Plant & Equipment (Net)9.09M9.95M8.42M7.61M6.47M
Goodwill000013.36M
Intangible Assets23.55M21.78M19.3M16.39M0
Long-term Investments35M1.28M000
Tax Assets00000
Other Non-current Assets121.71M164.08M78.98M65.95M1.06M
Total Non-current Assets189.34M197.08M106.7M89.95M20.89M
Total Assets1.07B886.18M831.68M685.35M670.77M
Account Payables114.92M64.6M52.76M40.37M45.35M
Short-term Debt00000
Tax Payables00000
Deferred Revenue2.65M2.2M2.34M00
Other Current Liabilities45.6M35.64M185.23M17.55M149.1M
Total Current Liabilities370.68M259.48M259.28M179.95M194.46M
Long-term Debt00006.08M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)14.06M13.15M2.51M00
Other Non-current Liabilities7.65M8.21M9.06M11.5M4.87M
Total Non-current Liabilities30.28M31.37M20.31M19.22M17.03M
Total Liabilities400.97M290.85M279.59M199.17M211.49M
Common Stock294.03M299M302.76M305.3M310.18M
Retained Earnings(1.42B)(1.53B)(1.59B)(1.67B)(1.71B)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity667.1M595.33M552.1M486.18M459.28M
Total Debt8.58M10.02M8.74M7.72M12.16M
Net Debt(210.88M)(207.65M)(190.52M)(113.32M)(122.7M)

Amarin Corporation plc

NASDAQ:AMRN

Intrinsic Alpha fair value

Locked

Current Price

$11.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.